Sky-high prices for orphan drugs may be causing insurers considerable concern, yet a slight majority continue to believe they can manage the costs, according to a new survey.
To wit, just 2 percent of beneficiaries covered by the surveyed plans have an orphan disease, which is defined as an ailment that afflicts 200,000 or fewer people. But rising prices for orphan drugs now account for roughly 9 percent of their total drug expenses. As a result, 77 percent of the payers say they are “extremely concerned” and 30 percent are “moderately concerned.”
About the Author Reprints
